James Baker, MD
Allergy & Immunology · Portland, ORNPI 1710982293
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,763 of the $3,937 with a category attached, or 70.2%. It is spread thinly across 23 manufacturers, the largest accounting for just 22.2%. 2025 is the largest year on record at $1,250, 9.2 times the $137 reported in 2019.
Across 111 payments — averaging $35.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biocryst Pharmaceuticals, Inc.$875
- Regeneron Healthcare Solutions, Inc.$460
- CSL Behring$411
- Sanofi$400
- Genentech USA, Inc.$288
- Takeda Pharmaceuticals U.S.A., Inc.$235
- plus $1K from 17 others
Across 4 payments — averaging $1610.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$4K
- Sanofi US Services Inc.$3K
What the payments were for
- Consulting fees$87522%
- Food & beverage$2,76370%
- Education$2998%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biocryst Pharmaceuticals, Inc. | 1 | $875 |
| Regeneron Healthcare Solutions, Inc. | 12 | $460 |
| CSL Behring | 17 | $411 |
| Sanofi | 18 | $400 |
| Genentech USA, Inc. | 11 | $288 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $235 |
| AstraZeneca | 3 | $186 |
| GSK | 8 | $176 |
| AbbVie(2 entities) | 2 | $174 |
| Galderma Laboratories, L.p. | 1 | $126 |
| Blueprint Medicines Corporation | 3 | $125 |
| Incyte Corporation | 1 | $96 |
| Biocryst US Sales Co., LLC | 4 | $76 |
| Pfizer | 3 | $48 |
| Novartis | 2 | $43 |
| Lilly USA, LLC | 2 | $41 |
| Cycle Pharmaceuticals Inc | 2 | $38 |
| Kaleo, Inc. | 1 | $29 |
| Shire North American Group Inc | 2 | $26 |
| Alk-abello, Inc | 1 | $26 |
| Pharming Healthcare, Inc. | 1 | $21 |
| Grifols USA, LLC | 1 | $20 |
| Merck | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,937 in reported general payments places this provider in the 60th percentile of 33 allergy & immunology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 23 | $1,005,568 |
| XolairOmalizumab | 72 | $273,879 |
| Dupixent SyringeDupilumab | 45 | $193,837 |
| Dupixent PenDupilumab | 25 | $89,757 |
| Fasenra PenBenralizumab | 13 | $75,584 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $61,995 |
| NucalaMepolizumab | 11 | $34,478 |
| Arnuity ElliptaFluticasone Furoate | 105 | $32,573 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $30,142 |
| Spiriva RespimatTiotropium Bromide | 32 | $18,320 |
| AlvescoCiclesonide | 30 | $11,006 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 71 | $10,777 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $9,674 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 46 | $9,022 |
| DuleraMometasone/Formoterol | 19 | $8,861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $235 | $1,005,56823 claims |
| GSKTrelegy Ellipta, Nucala, Arnuity Ellipta, Breo Ellipta | $176 | $159,188226 claims |
| MerckDulera | $18 | $8,86119 claims |
| AstraZenecaSymbicort | $186 | $7,01526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 33 allergy & immunology providers in Oregon.
Other allergy & immunology in Portland
- Shyam JoshiPortland$116K
- Anthony MontanaroPortland$25K
- Karen AnsteyPortland$20K
- Michael OsbornePortland$11K
- Jessica MacdougallPortland$11K
- Renganathan SrinivasanPortland$5K
- Cristina SwansonPortland$3K
- Michael NoonanPortland$2K
- Gregory OwensPortland$1K
- Navid ZiaiePortland$530
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.